Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
An expert who watches Evommune thinks the company is still doing well, but doesn't think the stock price will go as high as they thought before. When experts lower their price guesses, it usually means they found new information to think about.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.